Sajan Javad A, Kerschner Joseph E, Merati Albert L, Osipov Vladimir, Szabo Sara, Blumin Joel H
Departments of Otolaryngology & Communication Sciences, Medical College of Wisconsin, Milwaukee, USA.
Arch Otolaryngol Head Neck Surg. 2010 Jan;136(1):7-11. doi: 10.1001/archoto.2009.179.
To quantify the prevalence of dysplasia and to evaluate the impact of use of cidofovir in recurrent respiratory papilloma biopsy specimens obtained from a pediatric population.
Retrospective review of patient medical records and histopathologic test results from January 1, 1998, through December 31, 2008.
Children's Hospital of Wisconsin.
Patients with a history of operation treated for recurrent respiratory papillomatosis.
The presence or absence of dysplasia identified in a papilloma specimen and patient characteristics, such as age of initial presentation, number of operations, tobacco exposure, treatment for reflux, and use of cidofovir, were quantified.
Treatment for recurrent respiratory papillomatosis was identified in 21 patients. Age at initial diagnosis ranged from 8 months to 14 years. A total of 123 recurrent respiratory papillomatosis specimens in 20 patients were identified. Dysplasia was seen in less than 1% of samples (1/123), which represents 5% of total patients. Seven patients (35%) received cidofovir treatment and none of them developed dysplasia. These data demonstrate a lack of correlation between cidofovir treatment and dysplasia, with the P value being nonsignificant (Fisher exact test, P=.4).
Dysplasia is a rare event in pediatric recurrent respiratory papillomatosis, and there does not appear to be an association between the use of cidofovir and dysplastic changes.
量化发育异常的患病率，并评估西多福韦在从儿科人群获取的复发性呼吸道乳头状瘤活检标本中的使用影响。
回顾性分析1998年1月1日至2008年12月31日期间患者的病历和组织病理学检查结果。
威斯康星儿童医院。
有复发性呼吸道乳头状瘤病手术治疗史的患者。
量化乳头状瘤标本中是否存在发育异常以及患者特征，如首次发病年龄、手术次数、烟草暴露情况、反流治疗情况和西多福韦的使用情况。
确定了21例复发性呼吸道乳头状瘤病患者。初次诊断时的年龄范围为8个月至14岁。在20例患者中总共鉴定出123份复发性呼吸道乳头状瘤标本。发育异常在不到1%的样本中出现（1/123），占患者总数的5%。7例患者（35%）接受了西多福韦治疗，且无一例发生发育异常。这些数据表明西多福韦治疗与发育异常之间缺乏相关性，P值无统计学意义（Fisher精确检验，P = 0.4）。
发育异常在儿科复发性呼吸道乳头状瘤病中是罕见事件，并且西多福韦的使用与发育异常改变之间似乎没有关联。
